Literature DB >> 9041049

Establishment and characterization of conditionally immortalized stromal cell lines from a temperature-sensitive T-Ag transgenic mouse.

D Feuerbach1, E Loetscher, K Buerki, T K Sampath, J H Feyen.   

Abstract

We established bone marrow stromal cell lines from a transgenic mouse that harbors a temperature-sensitive mutant of the simian virus 40-derived large T-antigen under the control of a major histocompatibility complex (MHC) I promotor. These cell lines were screened for their ability to induce the formation of osteoclasts in a spleen cell/stromal cell coculture system. By means of this screen, five clones, referred to as marine bone marrow stromal clone 1 (mBMS-B1) mBMS-B2, mBMS-B14, mBMS-B18, and mBMS-B21, were selected for detailed characterization. Cell growth depends on culture conditions, i.e., cells grow at 33 degrees C in the presence of murine interferon-gamma, whereas cell proliferation ceases at 39 degrees C. The phenotype of the cells is also correlated with the culture conditions because the osteoclast inductive capacity is only seen at 39 degrees C, indicating that the cells undergo differentiation when the transforming agent is inactivated. These conditionally immortalized stromal cells can be induced to express a variety of markers that are typical for mature osteoblasts, e.g., alkaline phosphatase activity and expression of functional parathyroid hormone receptor after stimulation with soluble osteogenic protein 1 (sOP-1). mRNA analysis revealed the expression and regulation of osteopontin, osteonectin, and collagen alpha 1(I) as well as the inducibility of osteocalcin upon treatment with sOP-1. The cells have the potential to form mineralized nodules in supplemented medium. We observed expression of vascular cell adhesion molecule-1, which is stimulated upon treatment of the cells with 1 alpha,25-dihydrocholecalciferol after 4 days, indicating the presence of the receptor for this steroid. These cell lines represent a model to study mechanisms and factors involved in osteoblast differentiation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9041049     DOI: 10.1359/jbmr.1997.12.2.179

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  5 in total

1.  The retinoblastoma protein tumor suppressor is important for appropriate osteoblast differentiation and bone development.

Authors:  Seth D Berman; Tina L Yuan; Emily S Miller; Eunice Y Lee; Alicia Caron; Jacqueline A Lees
Journal:  Mol Cancer Res       Date:  2008-09       Impact factor: 5.852

2.  Impaired bone development and increased mesenchymal progenitor cells in calvaria of RB1-/- mice.

Authors:  Gabriel M Gutierrez; Elizabeth Kong; Yves Sabbagh; Nelson E Brown; Jong-Seo Lee; Marie B Demay; David M Thomas; Philip W Hinds
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-19       Impact factor: 11.205

3.  Terminal osteoblast differentiation, mediated by runx2 and p27KIP1, is disrupted in osteosarcoma.

Authors:  David M Thomas; Sandra A Johnson; Natalie A Sims; Melanie K Trivett; John L Slavin; Brian P Rubin; Paul Waring; Grant A McArthur; Carl R Walkley; Andrew J Holloway; Dileepa Diyagama; Jonathon E Grim; Bruce E Clurman; David D L Bowtell; Jong-Seo Lee; Gabriel M Gutierrez; Denise M Piscopo; Shannon A Carty; Philip W Hinds
Journal:  J Cell Biol       Date:  2004-12-06       Impact factor: 10.539

Review 4.  Osteosarcoma: prognosis plateau warrants retinoblastoma pathway targeted therapy.

Authors:  Sarah E Ballatori; Philip W Hinds
Journal:  Signal Transduct Target Ther       Date:  2016-03-25

5.  Wee1 inhibition by MK-1775 leads to tumor inhibition and enhances efficacy of gemcitabine in human sarcomas.

Authors:  Jenny M Kreahling; Parastou Foroutan; Damon Reed; Gary Martinez; Tiffany Razabdouski; Marilyn M Bui; Meera Raghavan; Douglas Letson; Robert J Gillies; Soner Altiok
Journal:  PLoS One       Date:  2013-03-08       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.